The company plans €7m investment in cyclotron for commercial production of FDG and also to construct GMP laboratories for research and development of new radiodiagnostic agents at the over 6000m2 site.
The company has obtained all the necessary approvals for the new facility.
FDG is used in Positron Emission Tomography (PET) for the safe and early detection of the smallest cancer tumor foci.
With the completion of the construction, the company expects to supply FDG Fludeoxyglucose (18F) and other tracers for cancer imaging diagnostics to nuclear medical facilities in Warsaw and the central and eastern regions of Poland.